Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Retained Earnings (2023 - 2025)

CG Oncology's Retained Earnings history spans 3 years, with the latest figure at -$379.0 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 73.87% year-over-year to -$379.0 million; the TTM value through Dec 2025 reached -$379.0 million, down 73.87%, while the annual FY2025 figure was -$379.0 million, 73.87% down from the prior year.
  • Retained Earnings reached -$379.0 million in Q4 2025 per CGON's latest filing, down from -$337.7 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$129.9 million in Q4 2023 to a low of -$379.0 million in Q4 2025.
  • Average Retained Earnings over 3 years is -$234.4 million, with a median of -$218.0 million recorded in 2024.
  • Peak YoY movement for Retained Earnings: crashed 67.75% in 2024, then crashed 81.38% in 2025.
  • A 3-year view of Retained Earnings shows it stood at -$129.9 million in 2023, then plummeted by 67.75% to -$218.0 million in 2024, then plummeted by 73.87% to -$379.0 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Retained Earnings are -$379.0 million (Q4 2025), -$337.7 million (Q3 2025), and -$293.9 million (Q2 2025).